It has been shown in the literature that the favorable outcome of many HER2-positive breast cancer patients treated with chemotherapy and/or HER2-targeted therapy is attributed to active anti-tumor immunity, passive immunotherapy (115). Here, ERBB2 is linked to neoplasm.